Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 4/20 | 0.69 |
| ▸ | CALCA | P06881 | 2/20 | 0.69 |
| ▸ | NPY1R | P25929 | 1/20 | 0.69 |
| ▸ | NPY2R | P49146 | 1/20 | 0.69 |
| ▸ | NPY4R | P50391 | 1/20 | 0.69 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.69 |
| ▸ | GLP1R | P43220 | 11/20 | 0.65 |
| ▸ | GCGR | P47871 | 1/20 | 0.64 |
| ▸ | GIPR | P48546 | 1/20 | 0.64 |
| ▸ | TFPI | P10646 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20534064 | 1.00 | CXCR4 (0.69) | CXCR4CALCANPY1RNPY2RNPY4R | |
| SCHEMBL20534072 | 0.94 | NMBR (0.67) | CXCR4CALCANPY1RNPY2RNPY4R | |
| SCHEMBL29020839 | 0.94 | NMBR (0.67) | CXCR4CALCANPY1RNPY2RNPY4R | |
| Acetic Acid SCHEMBL29378226 | 0.93 | NMBR (0.66) | CALCAGLP1RGCGRGIPR | |
| SCHEMBL25311922 | 0.93 | NMBR (0.65) | CXCR4CALCAGLP1RGCGRGIPR | |
| SCHEMBL31359434 | 0.89 | CALCR (0.71) | GLP1RGCGRTFPI | |
| SCHEMBL29273722 | 0.89 | TFPI (0.63) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29588042 | 0.88 | CALCR (0.65) | CXCR4CALCANPY1RNPY2RNPY4R | |
| SCHEMBL29588160 | 0.88 | CALCR (0.66) | CXCR4CALCANPY1RNPY2RNPY4R | |
| SCHEMBL29587876 | 0.88 | CALCR (0.65) | CXCR4CALCANPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115920061-A | Combination therapy for HBV and HDV infection | MYR有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-115920061-A | Combination therapy for HBV and HDV infection | MYR有限公司 | 2023-04-07 | — | — | CN | disclosed |